L. Hansen Carl - 01 Dec 2022 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
01 Dec 2022
Net transactions value
$0
Form type
4
Filing time
05 Dec 2022, 11:13:30 UTC
Previous filing
21 Nov 2022
Next filing
23 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share Options (right to buy) Award $0 +925,069 +16% $0.000000 6,613,691 01 Dec 2022 Common Shares 925,069 $13.18 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.